Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Assets: 2019-2025

Historic Assets for Keros Therapeutics (KROS) over the last 6 years, with Sep 2025 value amounting to $742.8 million.

  • Keros Therapeutics' Assets rose 28.23% to $742.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $742.8 million, marking a year-over-year increase of 28.23%. This contributed to the annual value of $615.9 million for FY2024, which is 66.44% up from last year.
  • Latest data reveals that Keros Therapeutics reported Assets of $742.8 million as of Q3 2025, which was down 1.90% from $757.2 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Assets registered a high of $784.6 million during Q1 2025, and its lowest value of $226.7 million during Q2 2022.
  • Moreover, its 3-year median value for Assets was $485.8 million (2024), whereas its average is $532.5 million.
  • Its Assets has fluctuated over the past 5 years, first soared by 325.35% in 2021, then declined by 8.76% in 2022.
  • Over the past 5 years, Keros Therapeutics' Assets (Quarterly) stood at $255.3 million in 2021, then grew by 20.19% to $306.8 million in 2022, then climbed by 20.62% to $370.0 million in 2023, then soared by 66.44% to $615.9 million in 2024, then climbed by 28.23% to $742.8 million in 2025.
  • Its last three reported values are $742.8 million in Q3 2025, $757.2 million for Q2 2025, and $784.6 million during Q1 2025.